Navigation Links
New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma
Date:7/23/2014

Raleigh, NC (PRWEB) July 23, 2014

Researchers in Turkey say a compound called EF24, which is chemically similar to the yellow pigment in the spice turmeric, and an immunosuppressor called RAD001 helped scientists destroy mesothelioma cells in the lab. To read the full story on Surviving Mesothelioma, click here now.

Scientists at Gazi University in Ankara, Turkey pretreated mesothelioma cells and healthy mesothelial cells with both compounds before exposing them to two platinum-based chemotherapy drugs with promising results.

According to lead study author Dr. H. Ilke Onen, “Our preliminary results suggest that pretreatment with EF24 or RAD001 may reduce the cytotoxic effect of cisplatin on nonmalignant mesothelial cells and increase cell death response of malignant pleural mesothelioma cells.”

Reporting in Human & Experimental Toxicology, the team also found that healthy cells pretreated with the two compounds tended to experience less DNA damage when they were exposed to the chemotherapy drugs.

“Many of the serious side effects for mesothelioma patients on chemotherapy come from damage to healthy cells,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “This study is encouraging because it suggests there may be a way to protect those cells while still delivering a lethal dose of chemotherapy to mesothelioma tumors.”

To read the details of this exciting new study, including the next steps for research on EF24 and RAD001, see Mesothelioma Cells Respond Better to Chemotherapy Drug When Pretreated with Two Compounds now available on the Surviving Mesothelioma website.

Onen, H et al, “EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelioma (MET-5A) cells”, July 15, 2014, Human & Experimental Toxicology, Epub ahead of print. http://het.sagepub.com/content/early/2014/07/14/0960327114542965.abstract#corresp-1

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12031796.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. University of Utah researcher Robert Marc receives Paul Kayser International Award
2. New research finds pathogenic connection between autoimmune disorders and cancer
3. Research brings us nearer to understanding how neuro cells turn cancerous
4. Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research
5. SkillSurvey to Present Research on Contingent Workers at National Association for Health Care Recruitment IMAGE 2014 Conference
6. Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com
7. Hypatia Research Group Publishes “Enterprise Governance, Risk & Compliance: Best Practices, Maturity Models and 2014 ProductMatrix Vendor Evaluations”
8. Communication about female condom vital to young adults, UT Arlington researchers say
9. Chocolate Production in Canada Industry Market Research Report Now Available from IBISWorld
10. New research from Africa on pharmacomicrobiomics
11. Indoor Sports Facilities Management in the US Industry Market Research Report from IBISWorld Has Been Updated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... ... Journal of Pain Research has seen a significant increase in its ranking ... Scopus database (Elsevier B.V.) and is a measure of a journal's impact. It takes ... year period and also the importance of the journals where the citations came from. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... will discuss how to improve care by making data on heart procedures public ... The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart Disease ...
(Date:2/11/2016)... NJ (PRWEB) , ... February 11, 2016 , ... ... the call for nominations seeking candidates for the Board of Commissioners. Individuals interested ... passion, skills and experience with diversity of clinical practice settings and across allied ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, ... 334 spine surgeons to know in 2016 . The list consists of spine surgeons ... surgery. , Dr. Corenman understands the importance of clinical excellence; he has been ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the ... of DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel ... list. The panel’s goal is to recognize and promote technology entrepreneurship. , The ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Scientists from Silicon Biosystems Menarini today ... door to genetic analysis of previously preserved tumor ... isolate with 100 percent purity. Utilizing the com­pany,s ... various stages of development, the researchers were able ... are clinically relevant, and may change the way ...
(Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
(Date:2/11/2016)... 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced ... a Controlled Equity Offering SM Sales Agreement with ... Macaluso , Chairman and CEO, stated "During our most ... currently raising money and that we have enough money ... still complete all of our current objectives and nothing ...
Breaking Medicine Technology: